INDICATIONS

FULL PRESCRIBING INFORMATION

PATIENT INFORMATION

VISIT HEALTHCARE PROFESSIONAL SITE
Potential KRAZATI® patient, standing with a microphone, dressed in a yellow and blue jacket against a blue background.
Potential KRAZATI® patient, standing with a microphone, dressed in a yellow and blue jacket against a blue background.

Clinical 
TRIAL RESULTS

 

 

Not an actual patient.

KRAZATI was tested in combination with cetuximab in a clinical trial of 94 adults with KRAS G12C-positive advanced CRC who previously received certain chemotherapy medicines. 

The trial evaluated how many people responded to KRAZATI + cetuximab and how long their tumors responded to treatment.

34% saw tumors shrink.

(Objective response rate)

Based on 94 people, 32 people saw a decrease in tumor size. No person saw their tumors disappear completely.

34% of 94 colorectal cancer patients in a clinical trial saw their tumors shrink in size.
For those 32 patients who experienced a response to treatment for CRC, the duration of response was 5.8 months with KRAZATI®.

How long did the tumors respond to treatment?

(Duration of response)

Of those people (n=32) whose tumors responded to treatment, the median duration of response was 5.8 months.

-

Experiences with KRAZATI vary; speak with your doctor for more information. 

Possible side effects

KRAZATI can cause serious side effects, including stomach and intestinal (gastrointestinal) problems, changes in the electrical activity of your heart called QTc prolongation, liver problems, and lung or breathing problems.

Listen to your body, listen to yourself. If you experience any side effects, it’s important to talk to your healthcare provider right away.

Stomach and intestinal (gastrointestinal) problems
Stomach and intestinal side effects, including nausea, diarrhea, or vomiting, are common with KRAZATI but can also sometimes be severe. KRAZATI can also cause serious stomach and intestinal side effects such as bleeding, obstruction, inflammation of the colon (colitis), and narrowing (stenosis).

Call your healthcare provider if you develop any of the signs or symptoms of stomach or intestinal problems listed above during treatment with KRAZATI.

Your healthcare provider may prescribe an antidiarrheal medicine or anti-nausea medicine, or other treatment, as needed.

Changes in the electrical activity of your heart (called QTc prolongation)
Certain changes can occur in the electrical activity of your heart during treatment with KRAZATI and can be seen on a test called an electrocardiogram (ECG or EKG). QTc prolongation can increase your risk for irregular heartbeats that can be life-threatening, such as torsades de pointes, and can lead to sudden death.

  • You should not take KRAZATI if you have congenital long QT syndrome or if you currently have QTc prolongation

    • Your healthcare provider should monitor the electrical activity of your heart and the levels of body salts in your blood (electrolytes) especially potassium and magnesium before starting and during treatment with KRAZATI if you have heart failure, a slow heart rate, abnormal levels of electrolytes in your blood, or if you take a medicine that can prolong the QT interval of your heartbeat
    • Tell your healthcare provider if you feel dizzy, lightheaded, or faint, or if you get abnormal heartbeats during treatment with KRAZATI

Liver problems
Abnormal liver blood test results are common with KRAZATI and can sometimes be severe. Your healthcare provider should do blood tests before starting and during treatment with KRAZATI to check your liver function. Tell your healthcare provider right away if you develop any signs or symptoms of liver problems, including:

  • Your skin or the white part of your eyes turns yellow (jaundice)
  • Dark or “tea-colored” urine
  • Light-colored stools (bowel movements)
  • Tiredness or weakness
  • Nausea or vomiting
  • Bleeding or bruising
  • Loss of appetite
  • Pain, aching, or tenderness on the right side of your stomach area (abdomen)

Lung or breathing problems
KRAZATI may cause inflammation of the lungs that can lead to death. Tell your healthcare provider or get emergency medical help right away if you have new or worsening shortness of breath, cough, or fever.

The most common side effects of KRAZATI when used in combination with cetuximab for CRC include:
skin rash, nausea, diarrhea, vomiting, tiredness, muscle and bone pain, headache, dry skin, stomach pain, decreased appetite, swelling, low red blood cell count, cough, dizziness, constipation, nerve damage in the arms and legs.

Certain abnormal blood test results are common during treatment with KRAZATI, when used alone or in combination with cetuximab. Your healthcare provider will monitor you for abnormal blood tests and treat you if needed.

KRAZATI may cause fertility problems in males and females, which may affect your ability to have children. Talk to your healthcare provider if this is a concern for you.

The most common side effects (≥20%) of combination treatment with KRAZATI + cetuximab (N=94)

Common side effects of KRAZATI® for CRC are skin rash, nausea, diarrhea, vomiting, tenderness, muscle and bone pain, etc.

For managing side effects that can result from cetuximab, such as skin rashes, please talk to your doctor.

These are not all the possible side effects of KRAZATI. Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088. You may also report side effects at 1-844-647-2841.

CRC=colorectal cancer.

-

KRAZATI may provide a response to KRAS G12C. How to take KRAZATI >

IMPORTANT SAFETY INFORMATION

KRAZATI may cause serious side effects, including stomach and intestinal (gastrointestinal) problems, changes in the electrical activity of the heart called QTc prolongation, liver problems, and lung or breathing problems.

Before taking KRAZATI, tell your healthcare provider about all of your medical conditions, including if you:

 
  • have any heart problems, including heart failure and congenital long QT syndrome
  • have liver problems
  • are pregnant or plan to become pregnant. It is not known if KRAZATI can harm your unborn baby
  • are breastfeeding or plan to breastfeed. It is not known if KRAZATI passes into your breastmilk. Do not breastfeed during treatment and for 1 week after your last dose of KRAZATI

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. KRAZATI can affect the way other medicines work, and other medicines can affect how KRAZATI works.

KRAZATI can cause serious side effects, including:

 
  • Stomach and intestinal (gastrointestinal) problems. Stomach and intestinal side effects including nausea, diarrhea, or vomiting, are common with KRAZATI but can also sometimes be severe. KRAZATI can also cause serious stomach and intestinal side effects such as bleeding, obstruction, inflammation of the colon (colitis), and narrowing (stenosis)

    • Call your healthcare provider if you develop any of the signs or symptoms of stomach or intestinal problems listed above during treatment with KRAZATI

    • Your healthcare provider may prescribe an antidiarrheal medicine or anti-nausea medicine, or other treatment, as needed
       
  • Changes in the electrical activity of your heart called QTc prolongation. Certain changes can occur in the electrical activity of your heart during treatment with KRAZATI, and can be seen on a test called an electrocardiogram (ECG or EKG). QTc prolongation can increase your risk for irregular heartbeats that can be life-threatening, such as torsades de pointes, and can lead to sudden death

    • You should not take KRAZATI if you have congenital long QT syndrome or if you currently have QTc prolongation. See “Before taking KRAZATI, tell your healthcare provider about all of your medical conditions, including if you:”

      • Your healthcare provider should monitor the electrical activity of your heart and the levels of body salts in your blood (electrolytes) especially potassium and magnesium before starting and during treatment with KRAZATI if you have heart failure, a slow heart rate, abnormal levels of electrolytes in your blood, or if you take a medicine that can prolong the QT interval of your heartbeat

      • Tell your healthcare provider if you feel dizzy, lightheaded, or faint, or if you get abnormal heartbeats during treatment with KRAZATI
  • Liver problems. Abnormal liver blood test results are common with KRAZATI and can sometimes be severe. Your healthcare provider should do blood tests before starting and during treatment with KRAZATI to check your liver function. Tell your healthcare provider right away if you develop any signs or symptoms of liver problems, including:

    • your skin or white part of your eyes turns yellow (jaundice), dark or “tea-colored” urine, light-colored stools (bowel movements), tiredness or weakness, nausea or vomiting, bleeding or bruising, loss of appetite, pain, aching, or tenderness on the right side of your stomach area (abdomen)
       
  • Lung or breathing problems. KRAZATI may cause inflammation of the lungs that can lead to death. Tell your healthcare provider or get emergency medical help right away if you have new or worsening shortness of breath, cough, or fever

The most common side effects

 
  • The most common side effects of KRAZATI when used alone for NSCLC include: nausea, diarrhea, vomiting, tiredness, muscle and bone pain, kidney problems, swelling, decreased appetite, trouble breathing

  • The most common side effects when KRAZATI is used in combination with cetuximab for CRC include: skin rash, nausea, diarrhea, vomiting, tiredness, muscle and bone pain, headache, dry skin, stomach pain, decreased appetite, swelling, low red blood cell count, cough, dizziness, constipation, nerve damage in the arms and legs

Certain abnormal blood test results are common during treatment with KRAZATI, when used alone or in combination with cetuximab. Your healthcare provider will monitor you for abnormal blood tests and treat you if needed.

KRAZATI may cause fertility problems in males and females, which may affect your ability to have children. Talk to your healthcare provider if this is a concern for you.

These are not all the possible side effects of KRAZATI. Call your doctor for medical advice about side effects. You may report side effects to the FDA. Visit  fda.gov/medwatch, or call 1-800-FDA-1088. You may also report side effects to 1-844-647-2841.

Please see KRAZATI Patient Information. 

1914-US-2400473  10/24 

Bristol Myers Squibb logo

Site Map     Legal Notice     Privacy Policy     Your Privacy Choices    

© 2024 Mirati Therapeutics, Inc., a Bristol Myers Squibb company.
KRAZATI® and the related logo are registered trademarks of Mirati Therapeutics, Inc.

This website is intended for U.S. residents 18 years of age or older.

1914-US-2400471 10/24